558P - Oxaliplatin and erectile dysfunction

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Gastrointestinal Cancers
Presenter Pinar Dal
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors P. Dal1, M. Dincer1, B. Yildiz1, O. Kahraman2, M. Canhoroz3, D. Arik4, B. Başeskioğlu5, H. Yilmaz6
  • 1Medical Oncology, Eskişehir Osmangazi Üniversitesi-ESOGU-Meşelik Kampus, 26480 - Eskisehir/TR
  • 2Student, Eskişehir Osmangazi Üniversitesi-ESOGU-Meşelik Kampus, 26480 - Eskisehir/TR
  • 3Medical Oncology, Acıbadem Eskisehir Hastanesii, 26480 - Eskisehir/TR
  • 4Pathology, Eskişehir Osmangazi Üniversitesi-ESOGU-Meşelik Kampus, 26480 - Eskisehir/TR
  • 5Urology, Eskişehir Osmangazi Üniversitesi-ESOGU-Meşelik Kampus, 26480 - Eskisehir/TR
  • 6Bioistatistics, Eskişehir Osmangazi Üniversitesi-ESOGU-Meşelik Kampus, 26480 - Eskisehir/TR

Abstract

Background

Oxaliplatin is commonly used for advanced / metastatic colorectal cancer treatment. Peripheral Neuropathy is major dose limiting side effect. It is unclear whether Oxaliplatin causes autonomic neuropathy such as erectile dysfunction or not. In this study, we assessed male sexual function in successfully treated colon cancer patients.

Methods

Among male stage 2 and 3 colon cancer patients, medical records analyzed. Patients >65 years, history of pelvic surgery/radiotherapy and Erectile Dysfunction (ED), presence of stoma, cardiac and prostatic disorder were excluded.Patients had to be disease free and off-treatment for at least 6 months. Remaining 37 patients included the study. Patients completed a survey questionnaire that consisted of demographic characteristics,risk factors for ED and the International Index Of Erectile Function ( IIEF ) to assess their current level of sexual function. Peripheral neuropathy (PN) was assessed according to Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Patients designed; Group A: treated with non-Oxaliplatin chemotherapy (CT), such as Kapesitabin or 5-Fluorourasil, Group B defined as Oxaliplatin group, those treated with FOLFOX/CAPOX. IIEF score was defined as; no ED between score 26-30, ED exist between the score 0-25.

GROUP A n:17 (%45,9) GROUP B n:20 (%54,1) P
STAGE II III 17 (% 89,5) 0 (% 0) 2 (% 10,5) 18 (% 100) 0,000
BMİ 18,5-25,9 kg/m2 25,9-30 kg/ m2 >30 kg/ m2 4 (% 40) 10 (% 52,6) 3 (% 37,5) 6 (% 60) 9 (% 47,4) 8 (% 100) 0,700
SMOKE Never Current Ex smoker 5 (% 50) 3 (% 37,5) 9 (% 47,4) 5 (5 % 50) 5 (% 62,5) 10 (% 52,6) 0,856
ALCOHOL USE No Yes 14 (% 45,2) 3 (% 50) 17 (% 54,8) 3 (% 50) 1,000
DIABETES MELLİTUS No Yes 6 (% 48,5) 1 (% 25) 17 (% 51,5) 3 (% 75) 0,609
HYPERTENSİON No Yes 12 (% 42,9) 5 (% 55,6) 16 (% 57,1) 4 (% 44,4) 0,703
FSH Low Normal High 0 (% 0) 14 (% 48,3) 2 (% 40) 1 (% 100) 15 (% 51,7) 3 (% 60) 0,611
LH Normal High 12 (% 40) 4 (% 66,7) 18 (%60) 2 (% 33,3) 0,226
TESTESTERON Low Normal 4 (% 80) 12 (% 38,7) 1 (% 20,0) 19 (% 61,3) 0,149
P.NEUROPATHY Grade 0 Grade 1 12 (%85,7) 5 (%21,7) 2 (%14,3) 18 (78,3) 0,001
IIEF SCORE ED (-) ED (+) 11 (% 47,8) 6 (%42,9) 12 (% 52,2) 8 (%57,1) 0,519

Results

Mean age of Group A and B were 53,23 and 52,70 respectively (p:0,641). According to IIEF score, groups had some degree of ED, % 42,9 and % 57,1 (IIEF score 20,38 and 17,83) respectively (p:1,000). PN according to CTCAE were % 21,7 (n:5) and % 78,3 (n:18) (p:0,001), none of the patients had more than Grade 1 neuropathy.

Conclusions

These findings suggest that Oxaliplatin can cause peripheral neuropathy but not autonomic neuropathy such as ED. Further study and evaluation is necessary for exact decision. Therefore, the underlying pathology, either organic or psychological remains to be defined.

Clinical trial identification

Legal entity responsible for the study

Pinar Dal

Funding

Eskişehir Osmangazi University Medical School

Disclosure

All authors have declared no conflicts of interest.